BioSyent Inc. is a specialty pharmaceutical company that develops and sells healthcare products in Canada and internationally. Key strengths include a strong gross margin of 70.3% and a healthy current ratio of 2.07, indicating solid profitability and liquidity. However, concerns arise from a relatively low return on equity (6.2%) and a slight decline in stock price today (-0.70%). While the high margins suggest operational efficiency, the market cap of $191.68M may indicate undervaluation relative to its earnings potential.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Exceptional revenue growth of 40.9% YoY demonstrates strong market demand and competitive positioning.
Exceptional gross margin of 73.4% indicates strong pricing power and competitive moat.
Excellent operating cash flow margin of 20.7% indicates high-quality earnings.
Operating cash flow of $11.5M exceeds net income by 17%, indicating high-quality earnings with strong cash conversion.
Strong balance sheet with net cash position provides cushion for growth investments.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)